Next Article in Journal
Predictors of Recurrence after Radiotherapy for Non-Melanoma Skin Cancer
Previous Article in Journal
The Road Ahead for Cervical Cancer Prevention and Control
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 21
Issue 2
10.3747/co.21.1834
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Evidence-Based Guidelines for the Use of Tyrosine Kinase Inhibitors in Adults with Philadelphia Chromosome–Positive or Bcr-Abl–Positive Acute Lymphoblastic Leukemia: A Canadian Consensus

by
S. Couban
1,*,
L. Savoie
2,
Y. Abou Mourad
3,
B. Leber
4,
M. Minden
5,
R. Turner
6,
V. Palada
7,
N. Shehata
7,
A. Christofides
8 and
S. Lachance
9
1
Department of Medicine, Dalhousie University, Halifax, NS, USA
2
University of Calgary, Calgary, AB, USA
3
Leukemia and Bone Marrow Transplant Program of British Columbia, University of British Columbia, Vancouver, BC, USA
4
McMaster University, Hamilton, ON, USA
5
Department of Medical Oncology, University Health Network, University of Toronto, Toronto, ON, USA
6
Cross Cancer Institute, Edmonton, AB, USA
7
University of Toronto, St Michael’s Hospital, Toronto, ON, USA
8
Senior Medical Writer, Toronto, ON, USA
9
Hospital Maisonneuve–Rosemont, University of Montreal, Montreal, QC, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2014, 21(2), 265-309; https://doi.org/10.3747/co.21.1834
Submission received: 2 January 2014 / Revised: 5 February 2014 / Accepted: 4 March 2014 / Published: 1 April 2014

Abstract

Adult Philadelphia chromosome–positive (Ph+) or BCR-ABL–positive (BCR-ABL+) acute lymphoblastic leukemia (ALL) is an acute leukemia previously associated with a high relapse rate, short disease-free survival, and poor overall survival. In adults, allogeneic hematopoietic cell transplant in first remission remains the only proven curative strategy for transplant-eligible patients. The introduction of tyrosine kinase inhibitors (TKIS) in the treatment of patients with Ph+ or BCR-ABL+ ALL has significantly improved the depth and duration of complete remission, allowing more patients to proceed to transplantation. Although tkis are now considered a standard of care in this setting, few randomized trials have examined the optimal use of TKIS in patients with Ph+ ALL. Questions of major importance remain, including the best way to administer these medications, the choice of tki to administer, and the schedule and the duration to use. We present the results of a systematic review of the literature with consensus recommendations based on the available evidence.
Keywords: acute lymphoblastic leukemia; all; hematology; Philadelphia chromosome–positive; Ph+; tyrosine kinase inhibitors acute lymphoblastic leukemia; all; hematology; Philadelphia chromosome–positive; Ph+; tyrosine kinase inhibitors

Share and Cite

MDPI and ACS Style

Couban, S.; Savoie, L.; Mourad, Y.A.; Leber, B.; Minden, M.; Turner, R.; Palada, V.; Shehata, N.; Christofides, A.; Lachance, S. Evidence-Based Guidelines for the Use of Tyrosine Kinase Inhibitors in Adults with Philadelphia Chromosome–Positive or Bcr-Abl–Positive Acute Lymphoblastic Leukemia: A Canadian Consensus. Curr. Oncol. 2014, 21, 265-309. https://doi.org/10.3747/co.21.1834

AMA Style

Couban S, Savoie L, Mourad YA, Leber B, Minden M, Turner R, Palada V, Shehata N, Christofides A, Lachance S. Evidence-Based Guidelines for the Use of Tyrosine Kinase Inhibitors in Adults with Philadelphia Chromosome–Positive or Bcr-Abl–Positive Acute Lymphoblastic Leukemia: A Canadian Consensus. Current Oncology. 2014; 21(2):265-309. https://doi.org/10.3747/co.21.1834

Chicago/Turabian Style

Couban, S., L. Savoie, Y. Abou Mourad, B. Leber, M. Minden, R. Turner, V. Palada, N. Shehata, A. Christofides, and S. Lachance. 2014. "Evidence-Based Guidelines for the Use of Tyrosine Kinase Inhibitors in Adults with Philadelphia Chromosome–Positive or Bcr-Abl–Positive Acute Lymphoblastic Leukemia: A Canadian Consensus" Current Oncology 21, no. 2: 265-309. https://doi.org/10.3747/co.21.1834

APA Style

Couban, S., Savoie, L., Mourad, Y. A., Leber, B., Minden, M., Turner, R., Palada, V., Shehata, N., Christofides, A., & Lachance, S. (2014). Evidence-Based Guidelines for the Use of Tyrosine Kinase Inhibitors in Adults with Philadelphia Chromosome–Positive or Bcr-Abl–Positive Acute Lymphoblastic Leukemia: A Canadian Consensus. Current Oncology, 21(2), 265-309. https://doi.org/10.3747/co.21.1834

Article Metrics

Back to TopTop